ArticleBriefings in bioinformatics2025
Reinforcement learning with low-rank adaptation for targeted antimicrobial peptide design.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AI-Driven Discovery and Design of Antimicrobial Peptides: Progress, Challenges, and Opportunities.Probiotics and antimicrobial proteins · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) are emerging as promising alternatives to traditional antibiotics, offering solutions to antimicrobial resistance through diverse mechanisms. Despite their potential, current computational approaches for AMP design rarely address strain-specific targeting, limiting their clinical efficacy as bacterial strains exhibit unique membrane compositions and susceptibility profiles requiring tailored interventions. Furthermore, the limited availability of strain-specific training data presents a significant challenge, necessitating parameter-efficient learning approaches that can optimize AMP properties with minimal overfitting. This study introduces a novel AMP generation framework that integrates reinforcement learning with a Generative Pre-trained Transformer (GPT) model enhanced by Low-Rank Adaptation (LoRA) parameter-efficient fine-tuning. This approach enables the design of peptides optimized for multiple objectives, specifically antimicrobial activity and toxicity, tailored to individual pathogen strains. Our framework employs a two-stage learning process: pretraining on a large-scale peptide and AMP database to capture linguistic and contextual features, followed by reinforcement learning that leverages MIC (Minimum Inhibitory Concentration) and hemolysis prediction models to optimize antimicrobial potency and safety profiles. The integration of LoRA is crucial for efficiently adapting the model to strain-specific characteristics while addressing limited training data. The comparative analysis demonstrated our model's superior performance over existing AMP generation approaches in both activity and hemolytic toxicity metrics. An ablation study confirmed the contributions of reinforcement learning and LoRA. Furthermore, the model can generate peptides satisfying both activity and toxicity conditions for unseen strains, highlighting its capability to design AMPs for emerging pathogens. In addition, molecular dynamics (MDs) simulations confirmed that the generated peptides penetrate bacterial membranes, supporting antimicrobial activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.